OS Therapies Incorporated has reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of $10.4 million, a substantial increase from the $3.9 million loss reported in the same period last year. This increase in losses is attributed primarily to a rise in research and development expenses, which surged to approximately $7.4 million from $1.3 million year-over-year. The increase in R&D spending is linked to ongoing clinical trials and preparations for potential regulatory approvals for its lead product candidate, OST-HER2.

In terms of financial position, OS Therapies reported total assets of $7.3 million as of March 31, 2026, up from $6.8 million at the end of the previous fiscal year. The company’s cash reserves increased significantly to $917,552, compared to $269,830 at the end of 2025. However, total liabilities also rose sharply to $17.1 million, primarily due to an increase in accounts payable and accrued expenses, which climbed to $15.2 million from $11.4 million. The company’s accumulated deficit has now reached approximately $77.6 million.

Strategically, OS Therapies has made notable advancements, including the formation of two wholly-owned subsidiaries: OS Animal Health Corp and OS Therapies UK LTD. The latter is focused on research and development activities and has been operational since August 2025. The company is also actively pursuing regulatory interactions with the FDA and other international agencies regarding OST-HER2, with plans to submit a Biologics License Application (BLA) in the second quarter of 2026.

Operationally, OS Therapies has seen a significant increase in its engagement metrics, with the number of common shares outstanding rising to 39.3 million from 37.1 million at the end of 2025. The company has also engaged in various financing activities, including a recent registered direct offering that raised approximately $4.7 million, which will be used to support clinical development and general corporate purposes. Despite the current financial challenges, the company remains focused on advancing its product pipeline and achieving regulatory approvals, which it views as critical to its future growth and sustainability.

About OS Therapies Inc

OS Therapies Inc. is a biopharmaceutical company developing innovative immunotherapies and targeted treatments for osteosarcoma and other solid tumors. Its pipeline includes OST-HER2, an immunotherapy for rare cancers, and OST-tADC, a tunable antibody-drug conjugate platform targeting multiple cancers. The company focuses on clinical-stage development, leveraging proprietary technology, strategic collaborations, and regulatory designations to address unmet medical needs in oncology.

This description was generated via AI from an annual report. Updated 10 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.